Scientific Publications

Publications and presentations related to our proprietary NK cell immunotherapies (SNK01, SNK02) and NK cell activity test (NK Vue™).

Troculeucel (SNK01 Autologous)

Journal Publications

2022

Durable Responses Using SNK01 Autologous Enhanced Natural Killer Cells and Pembrolizumab for Chemotherapy-Resistant Advanced Sarcoma: Case Reports, Review of Literature and Future Perspectives.

Erlinda M. Gordon , Sant P. Chawla, Victoria S. Chua-Alcala, Don A. Brigham, Amir Ahari, Elan Younesi, Chrysler Valencia, Paul Y. Chang, Paul Y. Song

Oral Presentations

2024

NKGen Biotech Presents on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit

Paul Y. Song, MD
5th International Cell & Gene Therapy China Summit and Exhibition

View Presentation

NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12^th Annual Alzheimer’s & Parkinson’s Drug Development Summit

Paul Y. Song, MD
12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

View Presentation

Beneficial Effect on CSF and Plasma Tau Proteins and Cognitive Function in Alzheimer’s Disease Subjects Treated with Expanded Non-genetically Modified Autologous Natural Killer Cells (SNK01) [Tau2024]

Clemente Humberto Zuniga Gil, Blanca Isaura Acosta Gallo, Rufino Menchaca Diaz, Cesar Alejandro Amescua, Sean Hong, Lucia Hui, Hank Lee, Juan Mata, Paul Y. Chang, Katia Betito, Paul Y. Song

View Presentation

2022

Consistent Expansion and Activation of Autologous Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity (SNK01) from Heavily Pre-treated Patients with Advanced Solid Tumors [ASGCT 2022]

Sant Chawla, Victoria S. Chua, Erlinda M. Gordon, Ted Kim, Lucia M. Hui, Brenda L. Gibson, Paul Y. Chang, Debra Robinson, Paul Y. Song

Poster Presentations

2024

Subjects treated with expanded non-genetically modified autologous Natural Killer cells (SNK01) show changes in CSF α-synuclein and in cognitive function [AAIC 2024]

Clemente Humberto Zúñiga Gil, Blanca Isaura Acosta Gallo, Rufino Menchaca Diaz, Cesar Alejandro Amescua, Sean Hong, Lucia Hui, Hank Lee, Juan Mata, Paul Y. Chang, Katia Betito, Paul Y. Song

View Poster

2023

HER2-specific highly scalable CAR NK cell (anti-HER2-CAR SNK02) exhibits a significantly enhanced antitumor activity against HER2-expressing tumors as an off-the-shelf allogeneic immune cell therapy.(NKMax Co., Ltd. study) [SITC 2023]

Yong-hee Rhee, Hee-Sung Chae, Minji Kim, Seo-Gu Kang, Joungmin Lee, Yoon Mi Kang, Jae Seob Jung, Paul Y. Song, Yong Man Kim, Minchan Gil, NKMAX Co., Ltd., Seongnam, Republic of Korea; NKGen Biotech, Inc., Santa Ana, CA, USA

View Poster

Treatment of Alzheimer’s Disease Subjects With Expanded Non-genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity — Final Report of a Phase I Dose Escalation Study [CTAD 2023]

Clemente Humberto Zúñiga Gil, Blanca Isaura Acosta Gallo, Rufino Menchaca Díaz, César Alejandro Amescua, Lucia Hui, Hank Lee, Juan Mata, Paul Y. Chang, Katia Betito, and Paul Y. Song

View Poster

Use of Expanded Non-genetically Modified Natural Killer Cells (SNK01) with Enhanced Cytotoxicity in Patients with Alzheimer’s Disease – Interim Report of a Phase I Trial [WCN 2023]

Clemente Humberto Zúñiga Gil, Blanca Isaura Acosta Gallo, Rufino Menchaca Díaz, César Alejandro Amescua, Lucia Hui, Hank Lee, Juan Mata, Paul Y. Chang, Katia Betito, and Paul Y. Song

View Poster

Use of Expanded Non-Genetically Modified Natural Killer Cells (SNK01) with Enhanced Cytotoxicity in Patients with Alzheimer’s Disease — Interim Report of a Phase I Trial [AAIC 2023]

Clemente Humberto Zúñiga Gil, Blanca Isaura Acosta Gallo, Rufino Menchaca Díaz, César Alejandro Amescua, Sean Hong, Lucia Hui, Hank Lee, Juan Mata, Paul Y. Chang, Katia Betito, Paul Y. Song

View Poster

The Safety and Efficacy of SNK01 (autologous natural killer cells) in Combination with Cytotoxic Chemotherapy and/or Cetuximab after Failure of Prior Tyrosine Kinase Inhibitor Treatment in Non-small Cell Lung Cancer: Nonclincial Mouse Model and Phase I/IIa Clinical Study [ASCO 2023]

Myeong Geun Choi, Gun Woo Son, Dae-Hyun Ko, Wonjun Ji, Jin Kyung Rho, Jae Cheol Lee, Yong Man Kim, Jae Seob Jung, Paul Y. Song, Byeong Gon Yoon, Jong-min Jo, Mi Young Choi, Chang-Min Choi

View Poster

SNK01 Autologous Enhanced Natural Killer Cells and an Immune Checkpoint Inhibitor Control Tumor Growth in Rare Chemotherapy-Resistant Advanced Soft Tissue Sarcoma [ASGCT 2023]

Nadezhda Omelchenko, Neal Chawla, Victoria Chua-Alcala, Don A. Brigham, Sant P. Chawla, Paul Y. Song, Paul Y. Chang, and Erlinda M. Gordon

View Poster

2022

USFDA Authorized Compassionate Use of SNK01 (Autologous Non-Genetically Modified Natural Killer Cells With Enhanced Cytotoxicity) and Immune Checkpoint Inhibitors in Advanced Heavily Pre-treated Sarcoma. A Promising Regimen [ESMO 2022]

Victoria S. Chua, Sant P. Chawla, Erlinda Maria Gordon, Ted T. Kim, Brenda L. Gibson, Paul Y. Chang, Paul Y. Song

View Poster

Interim Analysis of a Phase I Study of SNK01 (Autologous Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) and Avelumab in Advanced Refractory Sarcoma [ASCO 2022]

Sant P. Chawla, Victoria S. Chua-Alcala, Erlinda Maria Gordon, Ted T. Kim, William Feske, Brenda L. Gibson, Paul Y Chang, Debra Robinson, Paul Y. Song

View Poster

Preliminary Analysis of a Phase I Study of SNK01 (Autologous Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) Monotherapy in Patients with Advanced Solid Tumors [ASCO 2022]

Victoria S. Chua-Alcala, Sant P. Chawla, Erlinda Maria Gordon, Ted T. Kim, Simranjit Sekhon, William Feske, Lucia Hui, Brenda L. Gibson, Paul Y Chang, Debra Robinson, Paul Y. Song

View Poster

The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors [ASCO 2022]

Anthony B. El-Khoueiry, Paul Y. Song, Jennifer Rubel, Dorna Y. Pourang, Christa Raab, Gabriele Hintzen, Michael Emig, Pilar Nava-Parada

View Poster

Sustained Responses/Disease Control Using Autologous Enhanced Natural Killer Cells Plus an Immune Checkpoint Inhibitor as Treatment for Rare Chemotherapy-Resistant Advanced Soft Tissue Sarcomas [CTOS 2022]

Nadezhda Omelchenko, Hripsime Chomoyan, Amir Ahari, Chrysler Valencia, Don A. Brigham, Sant P. Chawla, Paul Y. Song, Paul Y. Chang, Erlinda Gordon

View Poster

2021

Phase I study of escalating doses of ex vivo expanded, autologous natural killer cells in patients with pathologically confirmed cancer refractory to conventional therapy [CTOS 2021]

Sant P. Chawla, Simranjit Sekhon, Noufil Adnan, Ted T. Kim, Victoria T. Chua-Alcala, Ania Moradkhani, Steven Cha, Erlinda M. Gordon

A phase I/IIa randomized trial evaluating safety and efficacy of SNK01 (autologous natural killer cells) plus pembrolizumab in patients with stage IV non small cell lung cancer (NSCLC) who have failed first line platinum based therapy [SITC 2021]

Jin Kim, Yong Hee Cho, Dong Ha Kim, D ae Hyun Ko, Eun Ju Do, Sang Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang Min Choi

View Poster

The combination of CD16A/EGFR bispecific innate cell engager AFM24 with SNK01 NK cells promotes efficacious targeting and killing of EGFR+ tumor cells [AACR-NCI-EORTC 2021]

Jens Pahl, PhD

View Poster

2020

A Randomized Phase I/IIa Study to Evaluate the Safety and Efficacy of SNK-01 (autologous non-genetically modified natural killer cells with enhanced cytotoxicity) Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer

Eo Jin Kim, Dae-Hyun Ko, Wonjun Ji, Jin Kyung Rho, Jae Cheol Lee, Paul Y. Song, Chang-Min Choi

View Poster

Abstracts

2020

Phase I Study of SNK01 (autologous non-genetically modified natural killer cells with enhanced cytotoxicity) in Refractory Metastatic Solid Tumors

Sant P. Chawla, Katherine M Kim, Victoria S. Chua, Omid Jafari, Paul Y. Song

Natural Killer Cells and their Activity as a Potential Biomarker for Predicting Response to Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Paul Y. Song, Yong-Hee Cho, Myeong Geun Choi, Dong Ha Kim, Yun Jung Choi, Seon Ye Kim, Ki Jung Sung, Jae Cheol Lee, Sang-Yeob Kim, Jin Kyung Rho, Chang-Min Choi

SNK02 Allogeneic

Oral Presentations

2024

NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6^th Annual Allogeneic Cell Therapies Summit 2024

Paul Y. Song, MD
6th Annual Allogeneic Cell Therapies Summit 2024

View Presentation

Abstracts

2024

Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity (SNK02) in Patients with Advanced Solid Tumors without Lymphodepletion [ASCO 2024]

Victoria Chua, Sant P. Chawla, Erlinda Maria Gordon, William Feske, Lucia Hui, Hank Lee, Yoonmi Kang, Juan Mata, Katia Betito, Paul Y. Chang, Paul Y. Song

NK Vue™ NK Cell Activity Test

Poster Presentations

2021

The Potential Role of Peripheral Natural Killer Cells in Newly Diagnosed Inflammatory Bowel Disease or Colorectal Cancer

Francisco Trelles, Anabelle Cloutier, Andrea Herrera-Gayol, Roberto Rodriguez-Suarez, Katia Betito

View Poster

Journal Publications

2021

Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma

Hee Seung Lee,Galam Leem,Huapyong Kang,Jung Hyun Jo,Moon Jae Chung,Soo Jeong Jang,Da Hae Yoon,Jeong Youp Park,Seung Woo Park,Si Young Song,Seungmin Bang

Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine–platinum doublet plus trastuzumab

Hyungwoo Cho, Min-Hee Ryu, Hyung Eun Lee, Hyung-Don Kim & Yoon-Koo Kang

Changes in natural killer cell activity after surgery and predictors of its recovery–failure

Eun Y. Kim MD, PhD,Tae H. Hong MD, PhD

Natural killer cell activity level in colorectal cancer screening in an average risk population

Jandos Amankulov, Dilyara Kaidarova, Zhamilya Zholdybay, Marianna Zagurovskaya, Oxana Shatkovskaya, Akmaral Ainakulova, Madina Orazgaliyeva

2020

Lower postoperative natural killer cell activity is associated with positive surgical margins after radical prostatectomy

Yu-Chuan Lu, Ming-ChiehKuo, Jian-Hua Hong, Fu-Shan Jaw, Chao-Yuan Huang, Jason Chia-Hsien Cheng, Hsiu-Ni Kung

Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer

Myeong Geun Choi,Yeon Joo Kim,Jae Cheol Lee,Jin Kyung Rho,Chang-Min Choi

Blood natural killer cells during treatment in recurrent ovarian cancer

Jon Røikjær Henriksen, Line Nederby, Frede Donskov, Marianne Waldstrøm, Parvin Adimi, Anders Jakobsen, Karina Dahl Steffensen

Peripheral Natural Killer Cell Activity is Associated with Poor Clinical Outcomes in Pancreatic Ductal Adenocarcinoma

Hee Seung Lee, Galam Leem, Huapyong Kang, Jung Hyun Jo, Moon Jae Chung, Soo Jeong Jang, Da Hae Yoon, Jeong Youp Park, Seung Woo Park, Si Young Song, Seungmin Bang

Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer

Yong-Hee Cho, Myeong Geun Choi, Dong Ha Kim, Yun Jung Choi, Seon Ye Kim, Ki Jung Sung, Jae Cheol Lee, Sang-Yeob Kim, Jin Kyung Rho & Chang-Min Cho

2019

Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients With Disseminated Cancer

Torben Frøstrup Hansen, Line Nederby, Ahmed H. Zedan, Inge Mejlholm, Jon R. Henriksen, Karina D. Steffensen, Caroline B. Thomsen, Louise Raunkilde, Lars Henrik Jensen, Anders Jakobsen

Natural Killer Cell Activity and Prostate Cancer Risk in Veteran Men Undergoing Prostate Biopsy

Adriana C. Vidal, Lauren E. Howard, Emily Wiggins, Amanda M. De Hoedt, Stephen L. Shiao, Simon Knott, Emanuela Taioli, Jay H. Fowke, Stephen J. Freedland